+1-518-621-2074 | US-Canada Toll Free Contact Us

Increasing Global Health Expenditure and Approval of Novel Drugs to Augment Growth of Global Depressive Disorder Market

about us

Published on : Sep 01, 2016

ALBANY, New York, September 01, 2016: A new market research study has been added by ResearchMoz.us to its vast collection of research reports. The 57-page research study, titled “Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020),” offers an in-depth analysis of the market, emphasizing on the current trends and primary growth factors. The key geographical segments, product segmentation, and the competitive scenario of the global depressive disorder market have been included in the research report.

The research report has made use of several analytical tools to identify the challenges and opportunities in the global depressive disorder market. Moreover, to provide a clear understanding, the study has presented the historical data and predicted figures of the market with the help of infographics, charts, and tables. The inputs added in the research study are expected to help the leading players in the market in formulating their strategies and policies effectively in the near future.

The increased expenditure on medicines and public health programs, the rising sales of prescription drugs, and the growing prevalence of smoking are some of the primary factors estimated to augment the growth of the global depressive disorder market in the coming few years. In addition, the increasing global health expenditure and the growing female population worldwide are anticipated to drive the global market in the near future. However, the severe side-effects of certain drugs, patent expiry, and strict drug regulations are expected to curtail the growth of the depressive disorder market across the globe in the forecast period.

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=784698

As per the research study, the global market for depressive disorder therapeutics is projected to witness significant growth in the coming few years owing to the patent expiry of blockbusters and the introduction of improved drugs. Furthermore, the growing awareness among the population regarding the emergence of new drugs and therapeutics is projected to generate promising opportunities for the leading players in the next few years. The approval of novel drugs and development of rapid acting drugs are also expected to fuel the growth of the overall market throughout the forecast period.

The global market for depressive disorder therapeutics has been categorized on the basis of geography into Europe, China, and the U.S. Among these regions, the U.S. accounts for a massive share in the global market, owing to the growing prevalence of schizophrenia, bipolar depression, and other depression disorders in the region. On the other hand, the rising awareness and improved medical facilities are some of the factors fuelling the growth of the depressive disorder market in China and other Asia Pacific countries.

The research report further covers the competitive landscape of the depressive disorder market across the globe and throws light on the prominent players operating in the market. The business overview, financial status, product portfolio, and recent events and developments of the leading players have been highlighted in the study to give a clear picture of the market. Some of the prominent players included in the study are Eli Lilly and Company, Lundbeck, Pfizer Inc., and AstraZeneca.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]